VINCライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States...

Stats
本日の出来高	1.72M
平均出来高	1.18M
時価総額	15.63M
EPS	$0 ( 2024-03-26 )
次の収益日	( $-0.260 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.0120 (1.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Izumi Raquel E.	Buy	123 750	Stock Option (right to buy)
2024-03-07	Seelenberger Alexander A.	Buy	93 750	Stock Option (right to buy)
2024-03-07	Hamdy Ahmed Md	Buy	146 746	Stock Option (right to buy)
2024-03-07	Thomas Tom C	Buy	93 750	Stock Option (right to buy)
2023-08-11	Seelenberger Alexander A.	Buy	10 500	Common Stock

INSIDER POWER
100.00
Last 97 transactions
Buy: 7 261 732 \| Sell: 1 766 942

ボリューム相関

長: -0.44 (neutral)

短: -0.91 (very strong negative)

Signal:(31.431) Neutral

Vincerx Pharma, Inc. 相関

10 最も正の相関
SVAC	0.929
PAIC	0.909
RMRM	0.901
TLGT	0.894
MTSL	0.893
SVOK	0.862
MODV	0.861
CLMT	0.858
BOXL	0.842
ABNB	0.839

10 最も負の相関
AMRB	-0.955
NETE	-0.938
MMAC	-0.917
RAVN	-0.869
SRAC	-0.86
SBBP	-0.859
LWAC	-0.855
MGPI	-0.841
BOCH	-0.836
SHSP	-0.808

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Vincerx Pharma, Inc. 相関 - 通貨/商品

-0.72
( moderate negative )

-0.77
( moderate negative )

0.00
( neutral )

0.16
( neutral )

Vincerx Pharma, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-915 000 (0.00 %)
EPS:	$-1.890

FY	2023
収益:	$0
総利益:	$-915 000 (0.00 %)
EPS:	$-1.890

FY	2022
収益:	$0
総利益:	$-939 000 (0.00 %)
EPS:	$-2.72

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-7.48

Financial Reports:

No articles found.

Vincerx Pharma, Inc.

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.